Welcome to our dedicated page for EyePoint Pharmaceuticals news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint Pharmaceuticals stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. The company is committed to developing and commercializing ophthalmic products aimed at treating serious retinal diseases. EyePoint leverages its proprietary Durasert® technology, a sustained intraocular drug delivery system, to create treatments that can provide continuous therapeutic effects for extended periods.
EyePoint Pharmaceuticals has made significant strides in the field of retinal disease treatments. Its lead product candidate, DURAVYU™ (previously known as EYP-1901), is an investigational treatment for VEGF-mediated retinal diseases. This product combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert® technology to offer sustained delivery and improved patient outcomes. DURAVYU™ is currently undergoing clinical trials for conditions such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).
The company also has several other promising candidates in its pipeline, including EYP-2301, a TIE-2 agonist, and razuprotafib, formulated with Durasert® technology to potentially enhance treatment outcomes for serious retinal diseases.
EyePoint’s innovative approach extends beyond product development to strategic partnerships and collaborations. The company has secured exclusive licenses for vorolanib from Equinox Sciences for all ophthalmic uses outside of China, Macao, Hong Kong, and Taiwan. Additionally, EyePoint has FDA-approved products such as RETISERT® and YUTIQ® that are based on its proprietary drug delivery technology.
Financially, EyePoint Pharmaceuticals has shown a solid performance with total net revenue of $46.0 million for the year ended December 31, 2023, compared to $41.4 million for the previous year. This growth is driven primarily by revenues from royalties and collaborations. The company has also strengthened its financial position with $331.1 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
EyePoint is dedicated to driving innovation in ophthalmology and improving the quality of life for patients with serious eye conditions. With a focus on advancing its robust pipeline through clinical development, EyePoint Pharmaceuticals continues to make headway in addressing unmet medical needs in retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a licensing agreement with Betta Pharmaceuticals to develop and commercialize EYP-1901 in China, Hong Kong, Macau, and Taiwan. This extends their collaboration established in 2020 for vorolanib's use in ophthalmic diseases, including diabetic macular edema (DME). EyePoint retains global rights for EYP-1901 outside these territories. The agreement is expected to accelerate the clinical development of EYP-1901, which is aimed at treating serious eye disorders, addressing significant unmet needs in the region.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced it will host a conference call on May 4, 2022, at 8:30 a.m. ET to discuss its first quarter 2022 financial results and recent corporate developments. The call can be accessed by dialing (877) 312-7507 for domestic or (631) 813-4828 for international listeners, using conference ID 9257913. Additionally, a live audio webcast will be available on the company’s website, along with a replay post-call.
EyePoint specializes in therapeutics for serious eye disorders, leveraging its Durasert® technology for sustained drug delivery.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced that CEO Nancy Lurker will participate in a fireside chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 9:30 am ET. The event will be accessible via a live webcast and an archived replay on the Investors section of the Company's website, available for 90 days post-event. EyePoint specializes in therapeutics for serious eye disorders, notably using its Durasert® technology for sustained drug delivery, with products like YUTIQ® and the pipeline candidate EYP-1901 targeting wet age-related macular degeneration.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the grant of non-statutory stock options to four new employees, totaling 56,500 shares. These options, approved by the Compensation Committee, were granted on April 14, 2022, with an exercise price of $12.69 per share. The awards aim to incentivize employment and have a ten-year term, vesting over four years, with 25% vesting after one year and the rest in monthly installments. EyePoint focuses on developing therapeutics for serious eye disorders, leveraging its Durasert technology for drug delivery.
On March 15, 2022, EyePoint Pharmaceuticals (NASDAQ: EYPT) granted non-statutory stock options to six new employees as inducement awards outside its 2016 Long-Term Incentive Plan. A total of 6,250 options were issued, each with an exercise price of $12.05, reflecting the closing stock price on the grant date. The options have a ten-year term, vesting 25% on the first anniversary and the remaining monthly over three years, contingent on continued employment. This move aims to attract talent to enhance its pipeline, including the Durasert®-based treatment for serious eye disorders.
EyePoint Pharmaceuticals has secured a $45 million loan agreement with Silicon Valley Bank, replacing its previous credit facility. This new arrangement lowers the interest rate from 12.5% to approximately 5%, leading to annualized savings of about $2.8 million. It comprises a $30 million term loan and a revolving credit facility of up to $15 million, primarily backed by the company’s accounts receivable. As of December 31, 2021, EyePoint had $211.6 million in cash and investments, enhancing its financial stability for future developments.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer, succeeding John Weet. With over 30 years of experience in regulatory affairs, Lefebvre previously led regulatory strategy at Hengrui USA and has a strong background in ocular drug approvals from her time at Bausch Health. Her expertise is seen as critical in advancing EyePoint's pipeline, particularly EYP-1901, aimed at treating retinal diseases. The company also granted her stock options for entering employment, compliant with Nasdaq rules.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported significant financial growth for 2021, with net product revenues increasing by 70% to $35.3 million compared to $20.8 million in 2020. The company also highlighted positive eight-month data from the Phase 1 DAVIO trial of EYP-1901 for wet AMD, with Phase 2 trials expected to commence in Q3 2022. However, the company also reported a net loss of $58.4 million, up from $45.4 million the previous year, attributed to increased operating expenses. Cash reserves reached $211.6 million, providing operational funding into late 2024.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that CEO Nancy Lurker will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 10:30 a.m. ET. This presentation will highlight the company's commitment to developing innovative therapeutics for serious eye disorders. Investors can access a live webcast and an archived replay through the company website for 90 days post-event. EyePoint's pipeline includes EYP-1901, targeting wet age-related macular degeneration, utilizing its Durasert® technology for sustained drug delivery.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call scheduled for March 3, 2022, at 8:30 a.m. ET, to discuss its Q4 and full-year 2021 financial results and corporate developments. Interested participants can join by calling (877) 312-7507 domestically or (631) 813-4828 internationally, using conference ID 5058194. This presentation will also be available via live audio webcast on the company's website, with a replay accessible post-event. EyePoint is focused on therapeutics to treat serious eye disorders, leveraging its Durasert® technology.
FAQ
What is the current stock price of EyePoint Pharmaceuticals (EYPT)?
What is the market cap of EyePoint Pharmaceuticals (EYPT)?
What does EyePoint Pharmaceuticals, Inc. (EYPT) specialize in?
What is DURAVYU™?
Where is EyePoint Pharmaceuticals headquartered?
What are the key products in EyePoint's pipeline?
How did EyePoint Pharmaceuticals perform financially in 2023?
What is the Durasert® technology?
Has EyePoint Pharmaceuticals received FDA approval for any products?
What are the geographical operational footprints of EyePoint Pharmaceuticals?
What is EyePoint's strategy for future growth?
How does EyePoint Pharmaceuticals generate revenue?
